newsfilter
← Earnings
Earnings Releases·

Cogent Biosciences — Third Quarter 2026 Earnings Summary

  • Financial Performance:

    • Cash, cash equivalents, and marketable securities totaled $791.1 million as of September 30, 2026, down from $792.3 million as of June 30, 2026.
    • Research and development expenses were $75.1 million for the third quarter of 2026, an increase from $69.0 million in the same period of 2025; this includes $7.5 million in non-cash stock compensation, compared to $5.4 million in 2025.
    • General and administrative expenses were $42.1 million for the third quarter of 2026, up from $14.4 million in the third quarter of 2025; this includes $9.4 million in non-cash stock compensation, compared to $5.2 million in 2025.
    • Net loss was $111.4 million for the third quarter of 2026, compared to a net loss of $80.9 million for the same period in 2025.
    • For the nine months ended September 30, 2026, total operating expenses were $323.4 million compared to $233.9 million in 2025, and net loss was $305.2 million compared to $226.4 million in 2025.
    • Interest income was $7.1 million for the third quarter of 2026, up from $3.9 million in 2025.
    • Total other income, net was $5.8 million for the third quarter of 2026, up from $2.4 million in 2025.
    • Working capital was $730.5 million as of September 30, 2026, compared to $846.4 million as of December 31, 2025.
    • Total stockholders' equity was $516.3 million as of September 30, 2026, compared to $636.4 million as of December 31, 2025.
  • Guidance and Future Outlook:

    • The company expects its cash balance to fund operations and capital expenditures into late 2028, extending well past all three pending PDUFA action dates for bezuclastinib.
    • Anticipated PDUFA action dates include November 30, 2026, for GIST; December 30, 2026, for NonAdvanced Systemic Mastocytosis (NonAdvSM); and June 29, 2027, for Advanced Systemic Mastocytosis (AdvSM).
    • The company plans to submit Investigational New Drug (IND) applications for its JAK2 and KRAS pipeline programs in the fourth quarter of 2026.
    • The company intends to complete dose escalation for CGT4255, a CNS-penetrant, selective mutant ErbB2 inhibitor.
  • Business Segments and Product Lines:

    • The company is preparing for the commercial launch of bezuclastinib in Gastrointestinal Stromal Tumors (GIST) with a commercial team now in place.
    • The FDA accepted the New Drug Application (NDA) for bezuclastinib in Advanced Systemic Mastocytosis (AdvSM).
    • An extension cohort of the PEAK trial was initiated to investigate bezuclastinib in combination with sunitinib in first-line GIST patients with exon 9 or exon 11 primary mutations.
    • The company plans to present multiple posters at the 68th Annual Meeting of the American Society of Hematology (ASH) in December 2026, featuring data from the SUMMIT trial on skin and neurocognitive symptoms, pathobiology follow-up, and a symptomatic comparison of NonAdvSM patients.
    • The SUMMIT sub-study will present first-look clinical results regarding patient benefits of switching from avapritinib to bezuclastinib.
  • Market and Competitive Landscape:

    • Cogent Biosciences focuses on developing precision therapies for genetically defined diseases, specifically targeting mutations in KIT, ErbB2, PI3Kα, KRAS, and JAK2.
    • The company highlights bezuclastinib's design to potently inhibit the KIT D816V mutation and other mutations in KIT exon 17, which drive Systemic Mastocytosis and advanced GIST.
  • Risks and Challenges:

    • Forward-looking statements regarding FDA approvals, commercial launches, cash runway, and clinical development timelines are subject to material risks and uncertainties, including those detailed in the company's Form 10-Q.
    • The company notes that new risks and uncertainties may emerge and that actual results may differ from forecasts or milestones disclosed.
  • Management Commentary and Tone:

    • Andrew Robbins, President and CEO, stated the company is prepared to execute on the anticipated bezuclastinib launch in GIST and is preparing for potential approvals in NonAdvSM and AdvSM.
    • Management expressed confidence in the company's position, citing a strong balance sheet and a world-class team to continue the vision of creating best-in-class therapies for rare, mutationally driven diseases.
  • Other Key Points:

    • The company announced upcoming investor conferences including the Guggenheim Healthcare Innovation Conference (November 10), UBS Global Biopharma Conference (November 17), Jefferies Global Healthcare Conference (November 17), and Piper Sandler Healthcare Conference (December 1).
    • Live webcasts and replays for these events will be available on the company's Investors & Media page.
    • The company is based in Waltham, MA, and Boulder, CO.
Company
COGENT BIOSCIENCES INC
Sector
Healthcare
Industry
Biotechnology